Ocular adverse events associated with amiodarone: A pharmacovigilance disproportionality analysis
Journal of Clinical Ophthalmology and Research · 2026-10 · 14 (4) · 416-422
DOI: 10.4103/jcor.jcor_247_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Ophthalmology and Research, online erschienen am 18.11.2026. Verfasst von Abdelrahman Abu Osba und 6 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Amiodarone is a widely used antiarrhythmic medication with known ocular adverse effects. This study aimed to evaluate ocular adverse events associated with amiodarone using a large pharmacovigilance database. Prior research has characterized individual ocular toxicities of amiodarone, yet no prior studies have systematically quantified the full spectrum of ocular adverse events using real-world pharmacovigilance data.
Aim
This study aimed to evaluate ocular adverse events associated with amiodarone using a large pharmacovigilance database.
Methods
Disproportionality analyses were conducted listing amiodarone as the primary suspect drug in the FAERS database. Ocular AEs reports between Q4 2003 and Q2 2025 were analyzed. The reporting odds ratios (RORs) for drug-AE pairs were compared with all other drugs in the database, and sensitivity analysis was performed using the information component.
Results
Among 13,378 AEs reports involving amiodarone, 567 (4.24%) contained at least one ocular adverse event, corresponding to 838 total ocular drug–event pairs. The mean age with reported AEs was 68.9 years. By absolute number, the most frequently reported ocular AEs were blindness (12.9%), keratopathy (9.1%), corneal deposits (7.0%), cornea verticillata (7.0%), and optic neuropathy (6.6%). By signal strength, the most disproportionately reported events were cornea verticillata (ROR = 452.71; 95% confidence interval [CI]: 333.25–614.99), keratopathy (ROR = 211.33; 95% CI: 165.03–270.61), pseudopapilledema (ROR = 164.16; 95% CI: 73.93–364.52), and corneal deposits (ROR = 159.99; 95% CI: 121.56–210.56).
Conclusions
To the authors’ knowledge, this study provides the first pharmacovigilance assessment of the full spectrum of amiodarone-associated ocular adverse events. This study identified increased reporting disproportionality for established corneal and optic nerve toxicities, as well as for less commonly reported retinal and functional visual disturbances.
Zitieren
APA
Osba, A. A., Osba, R. A., Rhyno, E., Abdelaal, A., Hussein, I., Bondok, M., & Pollmann, A. S. (2026). Ocular adverse events associated with amiodarone: A pharmacovigilance disproportionality analysis. Journal of Clinical Ophthalmology and Research, 14(4), 416-422. https://doi.org/10.4103/jcor.jcor_247_26
Vancouver
Osba AA, Osba RA, Rhyno E, Abdelaal A, Hussein I, Bondok M, et al. Ocular adverse events associated with amiodarone: A pharmacovigilance disproportionality analysis. Journal of Clinical Ophthalmology and Research. 2026;14(4):416-422. doi:10.4103/jcor.jcor_247_26
BibTeX
@article{Osba2026,
author = {Osba, Abdelrahman Abu and Osba, Roaa Abu and Rhyno, Emma-Lee and Abdelaal, Ahmed and Hussein, Isra and Bondok, Mostafa and Pollmann, Andre S.},
title = {Ocular adverse events associated with amiodarone: A pharmacovigilance disproportionality analysis},
journal = {Journal of Clinical Ophthalmology and Research},
year = {2026},
volume = {14},
number = {4},
pages = {416--422},
doi = {10.4103/jcor.jcor_247_26}
}
EUVIMED